KYNETIC Funds 9 Proof

LEXINGTON, Ky. (July 15, 2022) — The Kentucky Network for Innovation and Commercialization (KYNETIC) funded nine proof-of-concept projects in the Cycle 5 round of early-stage commercialization grants.

KYNETIC is a National Institutes of Health (NIH) funded Research Evaluation and Commercialization Hub (REACH) and part of the national NIH Proof of Concept Network.

The grants are awarded to faculty, staff and student teams across Kentucky for new, innovative products that have the potential to impact human health. All types of products (therapeutic, preventative, device, test, software) for any disease/health care-related area are eligible.

The KYNETIC program is led by the University of Kentucky (UK), University of Louisville (UofL), Kentucky Cabinet for Economic Development, and Kentucky Commercialization Ventures. Linda Dwoskin (senior associate vice president for research, special projects) is principal investigator and Ian McClure (associate vice president for research, innovation and economic impact, and executive director of UK Innovate) is a co-investigator on the KYNETIC grant awarded to UK.

KYNETIC distributed $325,000 in Cycle 5 and awardees included:

KYNETIC Cycle 6 pre-applications are due July 25, 2022 by 5 pm EST. KYNETIC Project Managers are available for consultation before you submit your pre-application and throughout the application process.

All of Kentucky's public, higher education institutions are eligible to apply. Applications are first evaluated by an internal advisory committee of higher education administrators across Kentucky. Finalists advance to review by an external review board of industry leaders and subject matter experts, which then makes award recommendations to the NIH for final approval.

For more information, visit the KYNETIC website.

Research reported in this publication was supported by the National Heart Lung and Blood Institute of the National Institutes of Health under Award Number U01HL152392. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

As the state's flagship, land-grant institution, the University of Kentucky exists to advance the Commonwealth. We do that by preparing the next generation of leaders — placing students at the heart of everything we do — and transforming the lives of Kentuckians through education, research and creative work, service and health care. We pride ourselves on being a catalyst for breakthroughs and a force for healing, a place where ingenuity unfolds. It's all made possible by our people — visionaries, disruptors and pioneers — who make up 200 academic programs, a $501 million research and development enterprise and a world-class medical center, all on one campus.

In 2022, UK was ranked by Forbes as one of the "Best Employers for New Grads" and named a "Diversity Champion" by INSIGHT into Diversity, a testament to our commitment to advance Kentucky and create a community of belonging for everyone. While our mission looks different in many ways than it did in 1865, the vision of service to our Commonwealth and the world remains the same. We are the University for Kentucky.